Sep 28, 2026 07:04AM
Sep 25, 2026 07:02AM
Sep 25, 2026 07:02AM
Sep 1, 2026 07:02AM
Sep 1, 2026 07:02AM
Aug 6, 2026 07:02AM
Jul 29, 2026 07:03AM FDA grants RMAT designation to Ocugen's OCU410 for dry AMD
Jul 29, 2026 07:01AM
May 5, 2026 08:34AM
May 5, 2026 08:32AM
Apr 1, 2026 07:02AM
Apr 1, 2026 07:02AM
Mar 24, 2026 07:45AM
Mar 24, 2026 07:45AM Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Mar 11, 2026 06:03AM
Mar 4, 2026 08:15AM
Mar 4, 2026 08:15AM
Mar 2, 2026 07:02AM
Mar 2, 2026 07:02AM
Jan 12, 2026 06:30AM
Jan 12, 2026 06:30AM Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy
Nov 5, 2025 06:30AM
Sep 2, 2025 07:02AM
Sep 2, 2025 07:02AM
Aug 1, 2025 08:25AM
Jul 21, 2025 07:30AM
Jul 21, 2025 07:30AM
Jul 21, 2025 07:30AM Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team
Jun 24, 2025 06:51AM
Jun 23, 2025 07:30AM
Jun 23, 2025 07:30AM
Jun 16, 2025 07:03AM
Jun 16, 2025 07:02AM
Jun 11, 2025 07:30AM
May 27, 2025 07:04AM Ocugen (OCGN) Granted Rare Pediatric Disease Designation for OCU410ST
May 27, 2025 07:02AM
May 9, 2025 08:01AM
Mar 5, 2025 07:02AM
Mar 3, 2025 09:01AM
Mar 3, 2025 09:00AM
Feb 27, 2025 08:48AM
Feb 27, 2025 08:46AM Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease
Feb 12, 2025 07:45AM
Feb 12, 2025 07:42AM
Feb 3, 2025 06:31AM
Feb 3, 2025 06:30AM
Jan 27, 2025 06:31AM
Jan 27, 2025 06:30AM
Nov 20, 2024 07:33AM Ocugen (OCGN) Granted EMA's Medicinal Product Designation for OCU410ST
Nov 20, 2024 07:30AM

332,168 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All